Upper Gastrointestinal Tract Lymphoma With Natalizumab: Evidence of Impaired Immune Surveillance?
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Sierra Morales F, Wright R, Novo J, Arvanitis L, Stefoski D, Koralnik I
. Glioblastoma in natalizumab-treated multiple sclerosis patients. Ann Clin Transl Neurol. 2017; 4(7):512-516.
PMC: 5497532.
DOI: 10.1002/acn3.428.
View
2.
Graf J, Aktas O, Rejdak K, Hartung H
. Monoclonal Antibodies for Multiple Sclerosis: An Update. BioDrugs. 2019; 33(1):61-78.
DOI: 10.1007/s40259-018-0327-9.
View
3.
. Immunosuppression and malignancy. Br Med J. 1972; 3(5829):713-4.
PMC: 1788691.
View
4.
Law J, Kim D, Sturgis A, Naina H
. Non-Hodgkin Lymphoma of the Stomach in a Patient Treated with Natalizumab. Clin Med Insights Oncol. 2015; 9:61-3.
PMC: 4489670.
DOI: 10.4137/CMO.S27142.
View
5.
Traub J, Pellkofer H, Grondey K, Seeger I, Rowold C, Bruck W
. Natalizumab promotes activation and pro-inflammatory differentiation of peripheral B cells in multiple sclerosis patients. J Neuroinflammation. 2019; 16(1):228.
PMC: 6858649.
DOI: 10.1186/s12974-019-1593-2.
View